• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

European Society for Medical Oncology (ESMO) - Articles and news items

older-breast-cancer-worse-outcome

Large study shows older breast cancer patients have worse outcomes

Industry news / 13 October 2016 / Niamh Louise Marriott, Digital Content Producer

Results showed that mortality was higher in patients over 70 who were either not tested with Oncotype DX or had a recurrence score result greater than 18…

boeringer-ingelheim-nsclc

Reduced risk of NSCLC death seen in Boehringer Ingelheim’s head-to-head trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

The trial investigated overall survival and the reduction in risk of death (14%) was observed for patients treated with afatinib versus gefitinib…

novartis-melanoma-3-years

Patient overall survival still strong three years after Novartis’ melanoma trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy…

phase-1-antibody-breast-cancer

Daiichi Sankyo Phase 1 HER2-targeting antibody drug safe and effective to treat breast cancer

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

DS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase…

cetuximab

Second-line cetuximab active beyond progression in quadruple wild-type patients with mCRC

Industry news / 6 July 2015 / Victoria White

Results from a study on the efficacy of cetuximab plus FOLFOX chemo as second-line treatment for patients with mCRC were presented at the ESMO 2015 congress…

regorafenib

Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer

Industry news / 3 July 2015 / Victoria White

The Phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)…

clinical-trials-regulation

ESMO highlights the opportunities and challenges to come from the EU Clinical Trials Regulation

Industry news / 28 May 2015 / Victoria White

ESMO, in collaboration with EORTC, have expressed their views on the EU Clinical Trials Regulation in an official position paper…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionWATCH NOW
+ +